Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported ...

Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental ...

Entered into an agreement to be acquired by Novartis for $7.00 per share in cash, with potential to receive an additional $7.00 per share in cash through a contingent ...

Novartis' established global development and commercial capabilities will enable this important new medicine to reach patients if approved," said Jay Hagan, CEO of Regulus Therapeutics.

Regulus Therapeutics Inc. (NASDAQ:RGLS) announced some great news today, which is that it would be acquired by Novartis AG (NVS) for $7 per share in cash. However, there is room for additional ...

SAN DIEGO, April 30, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ...

SAN DIEGO, May 8, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ...

Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion. The Swiss company will pay $7 a share in cash up-front through a ...

After announcing successful trial results for its lead mRNA treatment earlier this year, Regulus Therapeutics agreed to be acquired by Novartis. 1 This will add the potential kidney disease treatment ...

Analyst Price Forecast Suggests 50.83% Upside As of April 24, 2025, the average one-year price target for Regulus Therapeutics is $12.04/share. The forecasts range from a low of $6.06 to a high of ...